Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.80USD
17 Feb 2017
Change (% chg)

$0.70 (+5.79%)
Prev Close
$12.10
Open
$12.15
Day's High
$12.80
Day's Low
$11.90
Volume
165,295
Avg. Vol
88,902
52-wk High
$13.45
52-wk Low
$7.03

EPZM.OQ

Chart for EPZM.OQ

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes... (more)

Overall

Beta: 2.34
Market Cap(Mil.): $742.55
Shares Outstanding(Mil.): 58.01
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -1.85 -- --
ROI: -40.31 -4.08 13.06
ROE: -46.02 4.84 14.19

BRIEF-Epizyme elects Kevin Conroy to its board of directors

* Epizyme elects Kevin Conroy to its board of directors Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Epizyme receives positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

* Epizyme Inc - received a positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

Jan 19 2017

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

Nov 28 2016

BRIEF-Epizyme Q3 loss per share $0.42

* Says plans to report efficacy, safety and biomarker data from both phase 2 studies on tazemetostat in first half of 2017

Nov 03 2016

BRIEF-Epizyme appoints Pamela Strode as vice president

* Epizyme appoints Pamela Strode as vice president, regulatory affairs and quality assurance Source text for Eikon: Further company coverage:

Sep 29 2016

BRIEF-Epizyme earns $6 million from Glaxosmithkline for initiation of clinical development

* Earns $6 million milestone payment from Glaxosmithkline for initiation of clinical development with first in-class PRMT5 inhibitor

Sep 15 2016

BRIEF-Epizyme's Tazemetostat study surpassed pre-specified futility hurdle - committee

* Independent data monitoring committee confirmed that study cohort related to tazemetostat has surpassed its pre-specified futility hurdle

Sep 07 2016

More From Around the Web

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,114 -41.00
Novartis AG (NOVN.S) CHF76.70 -0.30
GlaxoSmithKline plc (GSK.L) 1,636.50 -3.00
Celgene Corporation (CELG.OQ) $121.16 +2.50

Earnings vs. Estimates